Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.

× No keyword cloud information.

34 in total

1. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.

Authors: Shinji Koba; Tsutomu Hirano; Gen Yoshino; Keiko Sakai; Taro Sakaue; Mitsuru Adachi; Takashi Katagiri
Journal: Atherosclerosis Date: 2002-01 Impact factor: 5.162

2. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors: G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal: Lancet Date: 2001-12-15 Impact factor: 79.321

Review 3. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Authors: John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal: Diabetes Care Date: 2008-04 Impact factor: 19.112

4. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study.

Authors: J R McNamara; P K Shah; K Nakajima; L A Cupples; P W Wilson; J M Ordovas; E J Schaefer
Journal: Atherosclerosis Date: 2001-01 Impact factor: 5.162

5. Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients.

Authors: Naoko Takayanagi; Tomio Onuma; Shinobu Kato; Kyoko Nishiyama; Takashi Nomiyama; Ryuzo Kawamori
Journal: Diabetes Res Clin Pract Date: 2004-12 Impact factor: 5.602

6. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors: Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321

7. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.

Authors: Rui Jiang; Matthias B Schulze; Tricia Li; Nader Rifai; Meir J Stampfer; Eric B Rimm; Frank B Hu
Journal: Diabetes Care Date: 2004-08 Impact factor: 19.112

8. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.

Authors: D J Betteridge; J M Gibson
Journal: Diabet Med Date: 2007-03-15 Impact factor: 4.359

9. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.

Authors: Masahiko Kurabayashi; Tsutomu Yamazaki
Journal: J Atheroscler Thromb Date: 2008-12-06 Impact factor: 4.928

10. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study.

Authors: Christian Berne; Annica Siewert-Delle
Journal: Cardiovasc Diabetol Date: 2005-06-03 Impact factor: 9.951

1 in total

Review 1. Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.

Authors: Hisato Takagi; Masao Niwa; Yusuke Mizuno; Hirotaka Yamamoto; Shin-nosuke Goto; Takuya Umemoto
Journal: Heart Vessels Date: 2013-05-05 Impact factor: 2.037

1 in total